ArticleNature communications2022
Pangenomic analysis of Chinese gastric cancer.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Identification of Potential Therapeutic Targets for Xihuang Pill in Breast Cancer: A Mendelian Randomization and Experimental Study.Breast cancer (Dove Medical Press) · 2026Article
- Acyl-CoA thioesterases and their derived lipid mediators: linking Acyl-CoA metabolic reprogramming to the tumor microenvironment.Frontiers in immunology · 2026Review
- APAV: An advanced pangenome analysis and visualization toolkit.PLoS computational biology · 2025Article
- RNF128 promotes gastric cancer progression by inhibiting autophagy-dependent ferroptosis through Beclin1 ubiquitination.Cell death discovery · 2025Article
- Comparative genomic analysis of Helicobacter pylori isolates from gastric cancer and gastritis in China.BMC cancer · 2025Article
- Gastric cancer genomics study using reference human pangenomes.Life science alliance · 2025Article
- Comprehensive discovery and functional characterization of the noncanonical proteome.Cell research · 2025Article
- Potential therapeutic targets for bladder cancer: a proteome-wide Mendelian randomization study.American journal of cancer research · 2025Article
- Pangenome and multi-tissue gene atlas provide new insights into the domestication and highland adaptation of yaks.Journal of animal science and biotechnology · 2024Article
- Human pangenome: far-reaching implications in precision medicine.Frontiers of medicine · 2024Article
- Emerging trends in clinical cancer genomic research.Cancer biology & medicine · 2023Article
- The pig pangenome provides insights into the roles of coding structural variations in genetic diversity and adaptation.Genome research · 2023Article
- Th1 cells inducing IFNγ response improves immunotherapy efficacy in gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Human Pangenomics: Promises and Challenges of a Distributed Genomic Reference.Life (Basel, Switzerland) · 2023Review
- Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.Cancer biology & medicine · 2023Review
- From Samples to Germline and Somatic Sequence Variation: A Focus on Next-Generation Sequencing in Melanoma Research.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pangenomic study might improve the completeness of human reference genome (GRCh38) and promote precision medicine. Here, we use an automated pipeline of human pangenomic analysis to build gastric cancer pan-genome for 185 paired deep sequencing data (370 samples), and characterize the gene presence-absence variations (PAVs) at whole genome level. Genes ACOT1, GSTM1, SIGLEC14 and UGT2B17 are identified as highly absent genes in gastric cancer population. A set of genes from unaligned sequences with GRCh38 are predicted. We successfully locate one of predicted genes GC0643 on chromosome 9q34.2. Overexpression of GC0643 significantly inhibits cell growth, cell migration and invasion, cell cycle progression, and induces cell apoptosis in cancer cells. The tumor suppressor functions can be reversed by shGC0643 knockdown. The GC0643 is approved by NCBI database (GenBank: MW194843.1). Collectively, the robust pan-genome strategy provides a deeper understanding of the gene PAVs in the human cancer genome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.